{"component": "clause", "props": {"groups": [{"snippet": "Notwithstanding anything contained herein to the contrary, Pfizer shall have the right to terminate this Agreement, either in its entirety or in relation to any Target and relevant Compounds and Products under this Agreement, at any time for any or no reason in its sole discretion by giving sixty (60) days\u2019 advance written notice to Arvinas.", "size": 5, "snippet_links": [{"key": "right-to-terminate-this-agreement", "type": "clause", "offset": [81, 114]}, {"key": "in-relation-to", "type": "clause", "offset": [142, 156]}, {"key": "at-any-time", "type": "clause", "offset": [226, 237]}, {"key": "no-reason", "type": "clause", "offset": [249, 258]}, {"key": "sole-discretion", "type": "clause", "offset": [266, 281]}, {"key": "notice-to", "type": "definition", "offset": [325, 334]}], "samples": [{"hash": "iMi8lfNULNA", "uri": "/contracts/iMi8lfNULNA#termination-by-pfizer", "label": "Research Collaboration and License Agreement", "score": 31.340862423, "published": true}, {"hash": "2uEVDoPG5aV", "uri": "/contracts/2uEVDoPG5aV#termination-by-pfizer", "label": "Research Collaboration and License Agreement", "score": 31.340862423, "published": true}, {"hash": "chpinkxbv8v", "uri": "/contracts/chpinkxbv8v#termination-by-pfizer", "label": "Research Collaboration and License Agreement (Arvinas Holding Company, LLC)", "score": 29.7008898015, "published": true}], "hash": "f1e3fd61746bc820bcbb41902efb1332", "id": 1}, {"snippet": "Pfizer shall have the right to terminate this Agreement under this Section 8.02(a) upon written notice to Customer if Customer breaches any material obligation hereunder, including without limitation failing to pay any amount due hereunder which is not subject to a bona fide dispute when due hereunder (as described in the last two (2) sentences of Section 4.02(b) hereof), within the time required for such payment and such payment default is not cured within [***] after the receipt of written notice to Customer specifying such payment default, and such other default is not cured within [***] after receipt of written notice to Customer specifying such other default. During the initial Term or any Extension Period, Pfizer shall have the right in its sole discretion to terminate this Agreement upon [***] prior written notice to Customer without cause.", "size": 3, "snippet_links": [{"key": "right-to-terminate-this-agreement", "type": "clause", "offset": [22, 55]}, {"key": "notice-to-customer", "type": "definition", "offset": [96, 114]}, {"key": "material-obligation", "type": "clause", "offset": [140, 159]}, {"key": "including-without-limitation", "type": "clause", "offset": [171, 199]}, {"key": "failing-to-pay", "type": "clause", "offset": [200, 214]}, {"key": "subject-to", "type": "definition", "offset": [253, 263]}, {"key": "bona-fide-dispute", "type": "definition", "offset": [266, 283]}, {"key": "time-required", "type": "definition", "offset": [386, 399]}, {"key": "payment-default", "type": "definition", "offset": [426, 441]}, {"key": "receipt-of-written-notice", "type": "definition", "offset": [478, 503]}, {"key": "other-default", "type": "definition", "offset": [558, 571]}, {"key": "after-receipt-of", "type": "clause", "offset": [598, 614]}, {"key": "during-the-initial-term", "type": "clause", "offset": [673, 696]}, {"key": "extension-period", "type": "definition", "offset": [704, 720]}, {"key": "discretion-to-terminate", "type": "clause", "offset": [762, 785]}, {"key": "prior-written-notice", "type": "definition", "offset": [812, 832]}, {"key": "without-cause", "type": "definition", "offset": [845, 858]}], "samples": [{"hash": "jtkL1yyFyq2", "uri": "/contracts/jtkL1yyFyq2#termination-by-pfizer", "label": "Api Supply Agreement", "score": 31.340862423, "published": true}, {"hash": "jItoSG41Az5", "uri": "/contracts/jItoSG41Az5#termination-by-pfizer", "label": "Api Supply Agreement (Clarus Therapeutics Inc)", "score": 25.3887748118, "published": true}, {"hash": "j4Kc08EVamf", "uri": "/contracts/j4Kc08EVamf#termination-by-pfizer", "label": "Api Supply Agreement (Clarus Therapeutics Inc)", "score": 25.1587953457, "published": true}], "hash": "2e56480d5ad9545809cfd701ccdb3e70", "id": 2}, {"snippet": "Pfizer shall have the right to terminate the license granted to Medarex under Section 2.1.1 and its associated obligations if and only if Medarex or its Affiliates or Sublicensees/Licensees materially breaches (a) this Agreement, (b) Section 2.1, 2.2 or 2.3 of the \u2587\u2587\u2587\u2587\u2587\u2587\u2587 License Agreement, or (c) Section 3.1 of the \u2587\u2587\u2587\u2587\u2587\u2587\u2587 License Agreement (solely where such breach has a material adverse effect on Pfizer\u2019s ability to Exploit Pfizer Products under the Licensed Patents (as defined in the \u2587\u2587\u2587\u2587\u2587\u2587\u2587 License Agreement), and Medarex or its Affiliates or its Sublicensees/Licensees fails to cure such breach (under clause (a), (b) or (c) of this Section 2.5.3) within thirty (30) days after written notice from Pfizer specifying the nature of such breach. Pfizer shall have the right to terminate the license granted to it under Section 2.1.2, and its associated rights, in whole or as to any portion of the Medarex Patents on written notice to Medarex.", "size": 2, "snippet_links": [{"key": "right-to-terminate", "type": "clause", "offset": [22, 40]}, {"key": "granted-to", "type": "definition", "offset": [53, 63]}, {"key": "section-21", "type": "clause", "offset": [78, 89]}, {"key": "this-agreement", "type": "clause", "offset": [214, 228]}, {"key": "the-\u2587", "type": "clause", "offset": [261, 266]}, {"key": "license-agreement", "type": "definition", "offset": [273, 290]}, {"key": "section-31", "type": "clause", "offset": [299, 310]}, {"key": "material-adverse-effect-on", "type": "definition", "offset": [376, 402]}, {"key": "ability-to", "type": "definition", "offset": [412, 422]}, {"key": "licensed-patents", "type": "clause", "offset": [457, 473]}, {"key": "under-clause", "type": "clause", "offset": [608, 620]}, {"key": "within-thirty", "type": "clause", "offset": [660, 673]}, {"key": "days-after", "type": "definition", "offset": [679, 689]}, {"key": "written-notice", "type": "definition", "offset": [690, 704]}, {"key": "nature-of", "type": "clause", "offset": [732, 741]}, {"key": "associated-rights", "type": "clause", "offset": [851, 868]}, {"key": "medarex-patents", "type": "definition", "offset": [907, 922]}, {"key": "notice-to", "type": "definition", "offset": [934, 943]}], "samples": [{"hash": "arJvCD4taUc", "uri": "/contracts/arJvCD4taUc#termination-by-pfizer", "label": "Cross License Agreement", "score": 31.340862423, "published": true}, {"hash": "3ALkEYmRdm1", "uri": "/contracts/3ALkEYmRdm1#termination-by-pfizer", "label": "Cross License Agreement (Medarex Inc)", "score": 21.0, "published": true}], "hash": "d78b477a31292d2db0f32874bab933b4", "id": 3}, {"snippet": "If this Agreement is terminated by Pfizer pursuant to Section 10.2, the license granted by Archemix to Pfizer pursuant to Section 6.4 shall survive and the license granted by Archemix to Pfizer pursuant to Section 6.5 shall survive solely as applied to Products being commercialized by Pfizer as of the effective date of termination or derived from Early Leads and Optimized Leads being developed by Pfizer as of the effective date of termination, if any, in each case subject to Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 406 of the Securities Act. Pfizer\u2019s continued payment of all milestone, Royalty and other payments under and in accordance with this Agreement with respect thereto.", "size": 2, "snippet_links": [{"key": "this-agreement", "type": "clause", "offset": [3, 17]}, {"key": "by-pfizer", "type": "clause", "offset": [32, 41]}, {"key": "pursuant-to-section", "type": "definition", "offset": [42, 61]}, {"key": "granted-by", "type": "definition", "offset": [80, 90]}, {"key": "to-pfizer", "type": "clause", "offset": [100, 109]}, {"key": "section-64", "type": "clause", "offset": [122, 133]}, {"key": "section-65", "type": "clause", "offset": [206, 217]}, {"key": "as-applied", "type": "definition", "offset": [239, 249]}, {"key": "effective-date-of-termination", "type": "clause", "offset": [303, 332]}, {"key": "each-case", "type": "definition", "offset": [459, 468]}, {"key": "subject-to", "type": "definition", "offset": [469, 479]}, {"key": "this-exhibit", "type": "definition", "offset": [492, 504]}, {"key": "secretary-of-the-commission", "type": "definition", "offset": [558, 585]}, {"key": "pursuant-to-the-company", "type": "clause", "offset": [586, 609]}, {"key": "confidential-treatment", "type": "definition", "offset": [635, 657]}, {"key": "under-rule", "type": "clause", "offset": [658, 668]}, {"key": "the-securities-act", "type": "clause", "offset": [676, 694]}, {"key": "payment-of", "type": "definition", "offset": [715, 725]}, {"key": "royalty-and-other-payments", "type": "clause", "offset": [741, 767]}, {"key": "in-accordance-with", "type": "definition", "offset": [778, 796]}], "samples": [{"hash": "9QMrBN6jjxB", "uri": "/contracts/9QMrBN6jjxB#termination-by-pfizer", "label": "Collaborative Research, Services and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}, {"hash": "7kTyHZlaUvC", "uri": "/contracts/7kTyHZlaUvC#termination-by-pfizer", "label": "Collaborative Research, Services and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}], "hash": "80122c01c078374e57343077e9acc415", "id": 4}, {"snippet": "Without limiting any other legal or equitable remedies that Pfizer may have, if this Agreement is terminated by Pfizer in accordance with Section 13.3 or if this Agreement is terminated in accordance with Section 13.2 and Auxilium is the breaching Party, then Pfizer shall have the option, in its sole discretion, to terminate this Agreement, in which case the provisions of Section 14.1 shall apply; provided, however, that such termination must be exercised within one hundred twenty (120) days after written notice of such breach by Pfizer to Auxilium pursuant to Section 13.2 or 13.3, as applicable.", "size": 2, "snippet_links": [{"key": "without-limiting", "type": "definition", "offset": [0, 16]}, {"key": "other-legal-or-equitable-remedies", "type": "clause", "offset": [21, 54]}, {"key": "by-pfizer", "type": "clause", "offset": [109, 118]}, {"key": "in-accordance-with", "type": "definition", "offset": [119, 137]}, {"key": "section-133", "type": "clause", "offset": [138, 150]}, {"key": "section-132", "type": "clause", "offset": [205, 217]}, {"key": "breaching-party", "type": "clause", "offset": [238, 253]}, {"key": "the-option", "type": "clause", "offset": [278, 288]}, {"key": "sole-discretion", "type": "clause", "offset": [297, 312]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [317, 341]}, {"key": "section-141", "type": "clause", "offset": [375, 387]}, {"key": "days-after", "type": "definition", "offset": [492, 502]}, {"key": "notice-of", "type": "clause", "offset": [511, 520]}, {"key": "breach-by", "type": "clause", "offset": [526, 535]}, {"key": "pursuant-to-section", "type": "definition", "offset": [555, 574]}], "samples": [{"hash": "gGDkDgcq3OF", "uri": "/contracts/gGDkDgcq3OF#termination-by-pfizer", "label": "Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc)", "score": 22.1608487337, "published": true}, {"hash": "begP3RDUyZy", "uri": "/contracts/begP3RDUyZy#termination-by-pfizer", "label": "Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "fc0490a080d3e1d034b6db320c4c395e", "id": 5}, {"snippet": "After this Agreement has been in effect for a period of [ ] months, during the next ensuring [ ], Pfizer may by notice terminate this Agreement, with or without cause. If Pfizer terminates this Agreement pursuant to this Section, it will make a termination payment within [ ] days equal to the Funding Payments which would otherwise have been due for the [ ] period from [ ] and will retain all rights and duties set forth in the License Agreement. If Pfizer does not elect to terminate this Agreement during the [ ] period described in this Section, the Agreement will continue according to its terms until its termination date.", "size": 2, "snippet_links": [{"key": "in-effect", "type": "definition", "offset": [30, 39]}, {"key": "period-of", "type": "definition", "offset": [46, 55]}, {"key": "by-notice", "type": "clause", "offset": [109, 118]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [119, 143]}, {"key": "with-or-without-cause", "type": "clause", "offset": [145, 166]}, {"key": "pursuant-to", "type": "definition", "offset": [204, 215]}, {"key": "termination-payment", "type": "clause", "offset": [245, 264]}, {"key": "equal-to", "type": "definition", "offset": [281, 289]}, {"key": "funding-payments", "type": "definition", "offset": [294, 310]}, {"key": "period-from", "type": "definition", "offset": [359, 370]}, {"key": "rights-and-duties", "type": "definition", "offset": [395, 412]}, {"key": "the-license-agreement", "type": "clause", "offset": [426, 447]}, {"key": "the-agreement", "type": "clause", "offset": [551, 564]}, {"key": "according-to", "type": "definition", "offset": [579, 591]}, {"key": "termination-date", "type": "definition", "offset": [612, 628]}], "samples": [{"hash": "fl48xZI6Y7Z", "uri": "/contracts/fl48xZI6Y7Z#termination-by-pfizer", "label": "Collaborative Research Agreement (Chemgenics Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "380eec66a2d29199cfcea95eadd46c1c", "id": 6}, {"snippet": "9.1 [*] months after the date of initiation of Pfizer Compound Production and occupancy of the Production Facility by Pfizer, Pfizer may terminate this Agreement, without cause, upon [*] months' notice to ArQule, effective at the conclusion of the [*]-month notice period. If Pfizer does not provide ArQule notice at that time, Pfizer may only terminate the Agreement pursuant to Section 8.3.\n9.2 If Pfizer terminates this Agreement pursuant to this Section, (i) Pfizer will pay ArQule a termination fee of [*] within [*] days of termination; (ii) the research license granted to Pfizer under Section 5 shall thereupon terminate; (iii) the sublease shall terminate and Pfizer shall have no further obligation thereunder (except for rent accrued and unpaid through the ------------------ *Confidential treatment has been requested for the marked portion.", "size": 2, "snippet_links": [{"key": "date-of", "type": "clause", "offset": [25, 32]}, {"key": "pfizer-compound", "type": "definition", "offset": [47, 62]}, {"key": "production-facility", "type": "clause", "offset": [95, 114]}, {"key": "by-pfizer", "type": "clause", "offset": [115, 124]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [137, 161]}, {"key": "without-cause", "type": "definition", "offset": [163, 176]}, {"key": "notice-to", "type": "definition", "offset": [195, 204]}, {"key": "conclusion-of", "type": "clause", "offset": [230, 243]}, {"key": "notice-period", "type": "definition", "offset": [258, 271]}, {"key": "terminate-the-agreement", "type": "clause", "offset": [344, 367]}, {"key": "section-83", "type": "clause", "offset": [380, 391]}, {"key": "termination-fee", "type": "definition", "offset": [488, 503]}, {"key": "to-pfizer", "type": "clause", "offset": [577, 586]}, {"key": "section-5", "type": "clause", "offset": [593, 602]}, {"key": "the-sublease", "type": "clause", "offset": [636, 648]}, {"key": "no-further-obligation", "type": "clause", "offset": [687, 708]}, {"key": "for-rent", "type": "definition", "offset": [728, 736]}, {"key": "confidential-treatment", "type": "definition", "offset": [788, 810]}], "samples": [{"hash": "2jg6w1Ud0tv", "uri": "/contracts/2jg6w1Ud0tv#termination-by-pfizer", "label": "Technology Acquisition Agreement (Arqule Inc)", "score": 18.0, "published": true}], "hash": "620224f766b8750bf2b949fb42ff9dd5", "id": 7}, {"snippet": "After this Agreement has been in effect for a period of eighteen (18) months, Pfizer may terminate this Agreement, with or without cause, upon six (6) months notice to Megabios. If Pfizer terminates this Agreement pursuant to this Section, it will make the payments which would otherwise have been due for such six (6) month period and will retain all rights and duties set forth in the License Agreement.", "size": 2, "snippet_links": [{"key": "in-effect", "type": "definition", "offset": [30, 39]}, {"key": "period-of", "type": "definition", "offset": [46, 55]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [89, 113]}, {"key": "with-or-without-cause", "type": "clause", "offset": [115, 136]}, {"key": "notice-to", "type": "definition", "offset": [158, 167]}, {"key": "pursuant-to", "type": "definition", "offset": [214, 225]}, {"key": "rights-and-duties", "type": "definition", "offset": [352, 369]}, {"key": "the-license-agreement", "type": "clause", "offset": [383, 404]}], "samples": [{"hash": "btDyRRcsl1q", "uri": "/contracts/btDyRRcsl1q#termination-by-pfizer", "label": "Collaborative Research Agreement (Megabios Corp)", "score": 18.0, "published": true}], "hash": "d02a04ec0109f717a961d2179ed8aa6a", "id": 8}, {"snippet": "Pfizer may terminate this Agreement: (A) upon 30 days prior written notice to Institution if: (i) the Protocol is materially modified in a way unacceptable to Pfizer, (ii) Study conduct is not completed within six months after the expected Study Completion date, (iii) the Study does not start within six months of the Effective Date, (iv) the Subject enrollment rate is significantly slower than outlined in the Protocol or needed to complete the Study by the Study Completion date; or (v) the Study design or objectives are no longer scientifically relevant or if Pfizer ceases production, commercialization or development of the Pfizer Product; or (B) immediately upon written notice to Institution if Principal Investigator becomes unavailable or withdraws from the Study and Pfizer and Institution are unable to agree upon a successor within 30 days after Pfizer is notified.", "size": 1, "snippet_links": [{"key": "terminate-this-agreement", "type": "clause", "offset": [11, 35]}, {"key": "notice-to", "type": "definition", "offset": [68, 77]}, {"key": "the-protocol", "type": "clause", "offset": [98, 110]}, {"key": "to-pfizer", "type": "clause", "offset": [156, 165]}, {"key": "study-conduct", "type": "clause", "offset": [172, 185]}, {"key": "not-completed", "type": "clause", "offset": [189, 202]}, {"key": "six-months", "type": "definition", "offset": [210, 220]}, {"key": "study-completion-date", "type": "definition", "offset": [240, 261]}, {"key": "the-study", "type": "definition", "offset": [269, 278]}, {"key": "the-effective-date", "type": "clause", "offset": [315, 333]}, {"key": "subject-enrollment", "type": "clause", "offset": [344, 362]}, {"key": "complete-the", "type": "clause", "offset": [435, 447]}, {"key": "study-design", "type": "definition", "offset": [495, 507]}, {"key": "development-of-the", "type": "clause", "offset": [613, 631]}, {"key": "pfizer-product", "type": "definition", "offset": [632, 646]}, {"key": "upon-written-notice", "type": "clause", "offset": [667, 686]}, {"key": "principal-investigator", "type": "definition", "offset": [705, 727]}, {"key": "days-after", "type": "definition", "offset": [850, 860]}], "samples": [{"hash": "bbIHgSAwYpG", "uri": "/contracts/bbIHgSAwYpG#termination-by-pfizer", "label": "Investigator Sponsored Research Agreement", "score": 32.3099420079, "published": true}], "hash": "7cf58fb27cad7746a0ce7fbc4903068f", "id": 9}, {"snippet": "Between June 1 and August 1, 2000, Pfizer may terminate this Agreement, with or without cause, by delivering written notice of termination to Mitokor, for a termination effective November 3, 2000. Upon Mitokor's receipt of such notice of termination by Pfizer, Mitokor may, at its sole option, terminate all work under the Research Plan unless otherwise agreed with Pfizer. If Pfizer terminates this Agreement pursuant to this Section, it will make funding payments which would have otherwise been due through November 3, 2000 and Pfizer will retain all rights and obligations as set forth in the License Agreement.", "size": 1, "snippet_links": [{"key": "terminate-this-agreement", "type": "clause", "offset": [46, 70]}, {"key": "with-or-without-cause", "type": "clause", "offset": [72, 93]}, {"key": "written-notice-of-termination", "type": "clause", "offset": [109, 138]}, {"key": "effective-november", "type": "clause", "offset": [169, 187]}, {"key": "receipt-of", "type": "clause", "offset": [212, 222]}, {"key": "notice-of-termination-by", "type": "clause", "offset": [228, 252]}, {"key": "all-work", "type": "clause", "offset": [304, 312]}, {"key": "research-plan", "type": "definition", "offset": [323, 336]}, {"key": "unless-otherwise-agreed", "type": "definition", "offset": [337, 360]}, {"key": "pursuant-to", "type": "definition", "offset": [410, 421]}, {"key": "funding-payments", "type": "definition", "offset": [449, 465]}, {"key": "rights-and-obligations", "type": "definition", "offset": [554, 576]}, {"key": "the-license-agreement", "type": "clause", "offset": [593, 614]}], "samples": [{"hash": "6sYKbswu2yT", "uri": "/contracts/6sYKbswu2yT#termination-by-pfizer", "label": "Collaborative Research and Development Agreement (Mitokor)", "score": 18.0, "published": true}], "hash": "b2320a5e029f6c16efa931709150d0d8", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ih50ZXJtaW5hdGlvbi1ieS1wZml6ZXIjMDAwMDAwMGEMogECZW4YACAA", "clause": {"size": 45, "children": [["termination-for-cause", "Termination for Cause"], ["termination-for-convenience", "Termination for Convenience"], ["general", "General"], ["termination-for-law-related-breach", "Termination for Law-related Breach"], ["notice-regarding-change-of-control", "Notice regarding Change of Control"]], "title": "Termination by Pfizer", "parents": [["term-and-termination", "Term and Termination"], ["term-termination-and-disengagement", "Term Termination and Disengagement"], ["termination", "Termination"], ["government-approvals-term-and-termination", "Government Approvals Term and Termination"], ["term-and-terminationand-supply-failure", "Term and Terminationand Supply Failure"]], "id": "termination-by-pfizer", "related": [["termination-by-xoom", "Termination by XOOM", "Termination by XOOM"], ["termination-by-icann", "Termination by ICANN", "Termination by ICANN"], ["termination-by-mps", "TERMINATION BY MPS", "TERMINATION BY MPS"], ["termination-by-viacord", "Termination by ViaCord", "Termination by ViaCord"], ["termination-by-\u2587\u2587\u2587\u2587\u2587", "Termination by \u2587\u2587\u2587\u2587\u2587", "Termination by \u2587\u2587\u2587\u2587\u2587"]], "related_snippets": [], "updated": "2025-07-07T12:37:53+00:00"}, "json": true, "cursor": ""}}